Ross Clark Ross Clark

Is it time to phase out the AstraZeneca vaccine?

A phial of Pfizer-BioNTech Covid-19 vaccine. (Photo by Justin Tallis - Pool / Getty Images)

We still await good data on the transmissibility of the Indian variants of Sars-CoV-2, something the government insists is vital as to whether the full reopening of the economy and society can go ahead as planned on 21 June. But we do now have some data on efficacy of the Pfizer and AstraZeneca vaccines against the Indian variant B.1.617.2 – whose triple mutation las led to worries that it might be able to sidestep the vaccines. A study lead by Public Health England finds that while the efficacy of both vaccines is slightly lower for the Indian variant compared with the Kent variant, the difference is not great.

While the efficacy of the AstraZeneca vaccine is good, the Pfizer vaccine is more effective still

Two doses of the Pfizer vaccine, it finds, prevent 88 per cent of symptomatic cases of the Indian variant and 93 per cent of symptomatic cases of the Kent variant. Two doses of AstraZeneca prevent 60 per cent of cases of the Indian variant and 66 per cent of cases of the Kent variant. The study also looked at the protective effect three weeks after a single dose. Pfizer was found to prevent 33 per cent of cases of the Indian variant and 49 per cent of cases of Kent variant. For AstraZeneca the corresponding figures were 33 per cent and 50 per cent. These figures are all for symptomatic cases; the study didn’t measure the effectiveness of vaccines in preventing hospitalisations and deaths – although we know from previous trials that both vaccines are more effective still at preventing serious cases than they are at preventing mild cases.

There are, as ever, some caveats. The study has yet to be peer-reviewed. It involves a far smaller number of cases of the Indian variant (1,054) than the Kent variant (11,621).

Already a subscriber? Log in

Keep reading with a free trial

Subscribe and get your first month of online and app access for free. After that it’s just £1 a week.

There’s no commitment, you can cancel any time.


Unlock more articles



Don't miss out

Join the conversation with other Spectator readers. Subscribe to leave a comment.

Already a subscriber? Log in